Anemia is common in patients with chronic kidney disease and is associated with a high
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …

Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …

For the past 3 decades, erythropoiesis-stimulating agents (ESA) in conjunction with iron
supplementation has been the mainstay of treatment for anemia in chronic kidney disease …

Roxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that
has demonstrated favorable safety and efficacy in the treatment of renal anemia. Recent …

The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is
regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of …

Background: Anemia is a common complication of chronic kidney disease. The hypoxia-
inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a new class of oral drugs for the …

Anemia is a common complication of chronic kidney disease; it is mainly treated with
erythropoiesis-stimulating agents (ESAs) and iron. Experimental studies extensively …

Methods Thromboembolic events with onset before and after week 12 were evaluated.
Baseline risk factors for thromboembolic events were investigated by Cox regression …

Background: Five types of HIF-PHIs have been authorized for anemia treatment in CKD
patients in China and Japan. These are enarodustat, roxadustat, daprodustat, vadadustat …